Parents Of Children With Rare Genetic Disorder See Hope In Drug Trial, But Others See Litany Of Red Flags

Ovid Therapeutics' drug for Angelman syndrome--a rare cognitive disease that currently has no treatment--saw a glimmer of success in a very small trial. The drug had beaten the placebo on only one metric and failed on a full 16 others, including measures of quality of life and ability to sleep. To investors, the ostensibly positive data looked cherry-picked. In other news at the convergence of pharma and public health: Alzheimer's, dengue fever, superbugs, statins and more.

from Kaiser Health News http://bit.ly/2H4jijv